Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tiansheng Pharmaceutical Group (002872) Fair Value & Analysis

Healthcare · CN · Market cap 1.6B CNY

Price¥4.83
Fair Value¥3.67
Upside-24.0%
Quality95/100
Evidence: Medium Range ¥2.75 – ¥4.60

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tiansheng Pharmaceutical Group (002872) currently trades at ¥4.83, while our model-based Fair Value estimate is ¥3.67 — implying the stock looks roughly 24.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, cardiovascular and cerebrovascular, urinary system, gynecological, orthopedic, cardiology, diabetes, anesthetic, and others. It also provides traditional Chinese medicines and glucose injection. The company was founded in 2001 and is headquartered in Chongqing, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Tiansheng Pharmaceutical Group (002872) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥3.67 versus a price of ¥4.83 — about −24% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002872?
Our 21-model fair value for Tiansheng Pharmaceutical Group is ¥3.67 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥4.83.
What is the quality score of 002872?
Tiansheng Pharmaceutical Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.